# FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET

> **NCT03726931** · NA · COMPLETED · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 40 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DIAGNOSTIC_TEST:** 18F-Fluorestradiol PET/CT scan

## Key facts

- **NCT ID:** NCT03726931
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-13
- **Primary completion:** 2023-01-29
- **Final completion:** 2023-01-29
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03726931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03726931, "FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03726931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*